News

ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.
Trump administration says it is trying to prevent war but raises eyebrows by calling for commitments from Australia and Japan ...